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ABSTRACT 
OBJECTIVE: Colorectal cancer (CRC) is one of the main causes of cancer deaths in the world. This cancer can 
be divided into non-metastatic and metastatic CRC stages. CD3+CD56+ NKT cell subsets are a minor T cell 
subset in peripheral blood and conduct the killing of tumor cells in direct manner. Little is obvious about levels 
and surface markers of these cells such as NKG2D in different cancers, especially in CRC. 
METHODS: We included 15 non-metastatic (low-grade), 11 non-metastatic (high-grade), 10 metastatic colorectal 
cancer patients and 18 healthy controls. The percentages of CD3+CD56+ NKT cells and NKG2D+CD56+ NKT 
cells from samples were analyzed by fl ow cytometry in peripheral blood mononuclear cells (PBMCs) of samples. 
RESULTS: We found that there was a signifi cantly lower number of NKG2D+CD3+CD56+ cells in peripheral 
blood of patients with metastatic colorectal cancer compared with normal controls (77.53 ± 5.79 % vs 90.74 ± 
9.84 %; p<0.01).
CONCLUSION: The fact that frequency of NKG2D+CD56+ NKT cells was signifi cantly lower in patients with 
metastatic colorectal cancer compared to healthy controls strengthens the hypothesis that NKT cells can play 
a substantial role in the protection against human colorectal cancer, and this opens up avenues for novel stud-
ies about elucidating the other aspects of tumor surveillance in CRC progression and immunotherapy (Tab. 2, 
Fig. 2, Ref. 46). Text in PDF www.elis.sk.
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Introduction
Colorectal cancer (CRC) is one of the main causes of cancer 
deaths in the world, especially in the developed countries. Based 
on TNM (Tumor/node/metastasis) system, this cancer can be di-
vided into non-metastatic (I-III) and metastatic (IV) CRC stages 
(1). Similar to other cancers, a tumor can be classifi ed as being of 
low or high grade (2).
Natural killer T (NKT) cells are innate-like T lymphocytes 
with unique activation and effector properties (3). The main fea-
tures of NKT cells are co-expression of NK cell markers and T cell 
molecules (especially pan T cell marker CD3), CD1d restriction 
(4,5). Totally, NKT cells are divided into three subsets, namely 
type I NKT cells also called invariant (i) NKT cells, type II NKT 
cells, and type III NKT or NKT-like cells (6). Some experiments 
indicate that NKT cells generate antitumor activity in solid tumors 
and certain hematologic forms of cancer (7). Some of these reports 
suggest a protective role for iNKT and NKT-like cells compared 
to type II NKT cells showing to be majorly immunosuppressive 
(8,9). In general, iNKT cells were diminished signifi cantly in 
solid tumors, and the low frequencies of peripheral blood iNKT 
cells associate with poor prognosis in plenty of cancers (10–12).
CD3+CD56+ NKT-like cells include roughly 5 to 15% of the 
peripheral T-cell pool. Owing to repeated exposure to antigen, 
these cells gently increase in absolute number in older persons 
but are absent in cord blood (1).
NKG2D (Natural Killer Group 2D; CD314) was found to 
be preferentially expressed by human natural killer (NK) cells, 
CD8+ T cells, and some auto-reactive CD4+ T cells (12–14). In 
NK cells, NKG2D functions as the primary activating receptor, 
while in T cells it acts as a co-stimulatory receptor that reinforces 
TCR-mediated activation (15–17). Consequently, NKG2D/NK-
G2DLs system may represent an important activation to begin 
a strong immune response to malignant cells (18). The NKG2D 
ligands (NKG2DLs) consist of a diverse array of proteins that are 
structurally related to MHC class I. The main targets recognized by 
NKG2D are MICA/B (MHC class I related molecules). NKG2D 
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ligands are extensively expressed on solid tumors and in some 
forms of leukemia (15). Hence, owing to the loss of these ligands 
in normal cells and their expression in some types of cell stress 
such as cancers, NKG2D is considered to be one of the molecules 
involved in immune surveillance, particularly in the early stage 
of tumor development (19–24). In other words, NKG2D and its 
ligands serve as a self-immunosensing system and alert for host 
immune defense in response to tumors (25).
The presence of MICs on many progressing neoplasms, in-
cluding breast, lung, gastric, renal, colon, ovarian, and prostate 
carcinomas and melanomas, indicates that MIC expression on 
tumors could enhance the immune evasion (26). During cancer 
progression, the immune pressure on the tumor may end up in the 
selection of cells devoid of NKG2D ligands. Accordingly, in the 
affected persons, most primary tumors appear to express NKG2D 
ligands, whereas more advanced tumors and metastasis express low 
levels (27–29). This situation has been associated with the trans-
acting effects of soluble MICs (sMICs) cleaved from solid tumors 
and leukemic cells by a tumor-related metalloproteinase (30–32), 
followed by down-regulation of NKG2D through promoting its 
internalization and lysosomal degradation on immune cells (30).
Also, NKG2D was expressed on the surface of a unique 
CD3+CD56+ NKT-like cell subset (12). CD3+CD56+ NKT-like 
cells are a minor T cell subset in the peripheral blood (<10%) 
and are at maximum in the liver (up to 30 %) (33). Considerably, 
these cells conduct non-MHC-restricted and MHC-restricted lysis 
of tumor target cells in direct cell-killing manner and displayed 
robust antitumor activity in adoptive transfer investigations (34–
38). To our knowledge, data demonstrated in our study regard-
ing the NKG2D expression state on systemic NKT-like cells and 
frequency of these cells in non-metastatic and metastatic cancer 
patients are still lacking. 
Materials and methods 
Patients’ and controls’ samples 
Heparinized peripheral blood was obtained from 36 patients 
with colorectal cancer attending the gastroenterology clinic of 
Al-zahra, khanevadeh, and seid-al-shohada hospitals, affi liated to 
Esfahan University of Medical Sciences, as well as 18 age- and 
sex-matched healthy volunteers. Written consent was obtained 
from all patients and healthy controls, and the study was approved 
by the Ethical Committee of Esfahan University of Medical Scienc-
es. The disease diagnosis was based on the presence of symptoms 
of constipation in recent 6 months, history of familial polyposis, 
anus bleeding and positive colonoscopy results in relation to non-
metastatic patients, and history of colorectal cancer with current 
tumor dissemination to other organs in metastatic patients. TNM 
system is applied to classify CRC in four stages (I, II, III, and IV). 
We used both WHO (low and high grades) and TNM systems for 
the grouping of patients as follows:
 − Normal: healthy individuals
 − Non-metastatic (low-grade): stages I & II
 − Non-metastatic (high-grade): stage III
 − Metastatic (distant metastasis): stage IV
Also, there is a checklist of histopathologic features to improve 
the standard of colorectal cancer reporting:
A: Histologic type assessed based on WHO classifi cation as 
follows: 
 − Adenocarcinoma
 − Mucinous adenocarcinoma
 − Signet-ring cell carcinoma 
 − Small-cell carcinoma
 − Squamous cell carcinoma
 − Adenosquamous carcinoma
 − Medullary carcinoma
 − Undifferentiated carcinoma (2) 
Peripheral blood mononuclear cell (PBMC) isolation 
The most common method for PBMC isolation, Ficoll-
Hypaque PBMC separation, was applied. Briefl y, fresh periph-
eral whole-blood samples with heparin coagulant were diluted in 
one-to-one ratio with PBS/2 % FBS solution. Then, the diluted 
blood sample was laid gently on Ficoll-Hypaque layer (sigma, 
St Louis, MO, USA) and fi nally, PBMC was separated from this 
solution via density centrifugation at 2,800 rpm for 20 min. The 
viability of isolated cells was more than 95% as assessed by try-
pan blue exclusion test. 
Flow cytometry
PBMC staining for FACS analysis was done with an optimized 
amount of the following fl uorochrome conjugated mAbs: CD3-
PerCp, CD56-FITC, NKG2D-PE, PerCp Mouse IgG1 κ Isotype 
Control, FITC Mouse IgG2b κ Isotype Control, and PE Mouse 
IgG1 κ Isotype Control. All mAbs with exception of NKG2D-PE 
and PE Mouse Isotype control (eBioscience; San Diego, CA; USA) 
were purchased from BD Bioscience (San Jose,CA, USA). The iso-
lated cell suspension was adjusted at 105–106 cells/ml and incubated 
with anti CD3, anti CD56 and anti NKG2D for 30 min at 4 ºC. Si-
multaneously, daily, we incubated a tube with isotype controls for 
these three color stains. Ultimately, the cells were fi xed with 0.5 % 
paraformaldehyde solution in case that evaluation is delayed. The 
three-color analysis on FACS caliber (BD) was used to demon-
strate the NKG2D expression on CD56+CD3+ as NKT-like cells. 
Statistics
Statistical analysis was performed using the SPSS19 statisti-
cal software. The results were evaluated by one-way ANOVA and 
Kruskal–Wallis tests. Probability values of less than 0.05 were re-
garded signifi cant. The results presented in text, tables and fi gures 
represent mean standard deviation (SD).
Results 
Characteristics of patients and healthy donors
Patients were classifi ed either in non-metastatic (low-grade; n 
= 15), and non-metastatic (high-grade; n = 11), or metastatic (n = 
10) groups (Tab. 1). All patients were enrolled to our study before 
surgery or chemotherapy to minimize the negative effect of these 
factors on their immune status. 
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In our study, 30 samples were from patients with adenocarci-
noma, and 6 cases were classifi ed as mucinous adenocarcinoma. 
Similarly to previous studies, in our study, other types of tumor 
were rare (2).
Frequency of CD3+CD56+ NKT-like cells in patients with 
colorectal cancer and normal subjects 
Our results showed no statistically signifi cant difference 
among metastatic or non-metastatic colorectal cancer patients 
and healthy controls. 
Frequency of NKG2D+ NKT-like cells in the study groups 
By three-color fl ow cytometry method, we found a signifi -
cantly lower number of NKG2D+CD3+CD56+ cells in peripheral 
blood of metastatic colorectal cancer compared with normal con-
trols (77.53 ± 5.79 % vs 90.74 ± 9.84  %; p< 0.01); nevertheless, 
no signifi cant differences were observed between non-metastatic 
patients and healthy subjects (Tab. 2, Figs 1A and 2). 
Mean fl uorescence intensity (MFI) of NKG2D expression on pe-
ripheral blood CD3+CD56+ cells in the patients and normal 
groups 
In agreement with the frequency of NKG2D+NKT-like cells, 
the MFI of NKG2D on these cells was signifi cantly reduced in 
the metastatic patients in comparison to the normal group (37.94 
±8.24 vs 50.36±8.75; p<0.005). Also, it was diminished less in-
tensely in the non-metastatic (high-grade) patients compared with 
healthy controls (41.56±7.99 vs 50.36±8.75; p<0.05) (Tab. 2, 
Figs 1B and 2). 
Feature Normal Non-metastatic      (low-grade)
Non-metastatic
(high-grade) Metastatic
Number – 18 15 11 10
Sex Female 8 7 4 3
Male 10 8 7 7
Age Minimum 29 40 43 44
Maximum 65 71 71 72
Tab. 1. Patient and healthy donor characteristics.
%





CD3+CD56+ cells in lymphocytes 5.32±3.98 6.99±2.73  5.29±3.06 4.76±2.64 0.3 
MFI of CD56 on CD3+CD56+ cells 52.36±14.96 48.42±20.40 40.27±19.36 48.85±17.69 0.38
NKG2D+CD3+CD56+ cells 90.74±9.84 86.31±9.64 82.74±12.39       77.53±5.79        0.009       
MFI of NKG2D on NKG2D+CD3+CD56+ cells 50.36±8.75           46.95±8.32         41.56±7.99        37.94±8.24       0.002
The results represent mean percent (±SD) of the cells and MFI (±SD) of NKG2D expression on the related cells.
Tab. 2. Mean frequency of CD3+CD56+ and NKG2D+CD3+CD56+cells and MFI of NKG2D on these cells in study groups.
Fig. 1. A) Frequency (= percentage) of circulating NKG2D+ NKT-like cells, and B) Mean fl uorescence intensity (MFI) of NKG2D expression on 
circulating NKT-like cells in the study patients vs normal controls. Signifi cant p (p < 0.05 or less) values are shown in both A & B.
A B




Despite representing a small portion of systemic lymphocytes, 
CD3+CD56+ NKT-like cells show strong antitumor activities in 
vitro and in vivo through direct cell killing combined with other 
unique abilities to mediate immune cell recruitment and prolifera-
tion (39). In the study, we enumerated circulating CD3+CD56+ 
NKT-like cells; but the obtained data did not show any signifi cant 
differences among frequencies of these cells in the study groups 
(Tab. 2). Besides NKT-like cells, a small proportion of Type I NKT 
(iNKT) cells are CD56+ (40, 41). The discrimination between 
these two (iNKT & NKT-like) subsets requires the use of CD1d 
loaded with α-GalCer (α-galactosylceramide) (42), lacking in our 
research. Thus, at this level, we could not determine the type of 
NKT cells in the patients and controls, and so we reported our re-
sults as CD3+CD56+ NKT cells. 
Jadidi et al. showed that the amount of NKT-like cells in pa-
tients with CLL was signifi cantly lower in comparison to healthy 
subjects and was inversely correlated with Treg cell proliferation 
and disease progression (43). It has already been demonstrated 
that Treg cells can suppress the proliferation, cytokine release 
and cytotoxic activity of NKT cells (44). However, in spite of 
increasing Treg cell levels in CRC, the role of these cells in CRC 
is currently under debate. For example, Blatner et.al displayed 
that in both human CRC and murine polyposis, the interaction 
between mast cell and Treg cell contributes to systemic regula-
tory T cell dysfunction, and switches from suppressing to gen-
erating potently immune suppressive, but proinfl ammatory Treg 
cells (ΔTreg) (45) and this may be a convincing reason for our 
results about frequency of CD3+CD56+ NKT cells contrary to 
the other tumor studies.
One of the important mechanisms employed by many can-
cers such as colon carcinoma, to promote immune evasion is 
the release of soluble forms of NKG2D ligands such as MICs, 
and consequential down-regulation of NKG2D expression with 
severe defects in cytotoxic activities of CD3+CD56+ NKT-like 
cells similar to NK and CTLs (32, 39, 46). Regarding the lack of 
previous data about colorectal cancer, in this work, we indicated 
FL1-H
Fig. 2. Three-color fl ow cytometric analysis of NKG2D+CD3+CD56+ (NKG2D+ NKT-like) cells. First, lymphocytes gated in FSc (forward light 
scatter)-SSc (side light scatter) dot plot and then CD3+CD56+ gated in CD3-PerCp intensity vs. CD56-FITC intensity. Consequently FACS 
histograms show frequency (= percentage) of NKG2D+ NKT-like cells and MFI of NKG2D on these cells in the upper of each histogram. Col-
orless histograms represent isotype control antibodies and color histograms (green) show NKG2D as third color in FACS.
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that the frequency of systemic CD3+CD56+ NKT cells and NK-
G2D expression on these cells decrease during the progression 
of colorectal cancer, especially in metastatic patients (Fig. 1 and 
Tab. 2). CD3+CD56+ NKT-like cells have been reported to induce 
NK-sensitive target U937 cell and NK-resistant Raji cell lysis in a 
non-MHC-restricted manner (2); whether NKG2D is engaged in 
the cell killing induced by CD3+CD56+ NKT-like cells remains 
unknown. The results of Wang et.al implied that the NKG2D re-
ceptor plays a fundamental role in cytolysis of ovarian and pros-
tate cancer cells by CD3+CD56+ NKT-like cells, and this killing 
mediated by NKG2D is independent of TCR stimulation (39). The 
underlying mechanism has been associated with the trans-acting 
effects of sMICs cleaved from solid tumors and leukemic cells 
by a tumor-related metalloproteinase (31, 32). The engagement 
of sMICs then promotes NKG2D internalization and degradation 
in NK cells and CTLs. Although, we did not assess the circulating 
MICs levels in study groups to determine the correlation between 
ligands and lower NKG2D expression on CD56+NKT cells in 
colorectal cancer, there are some documents consistent with these 
fi ndings that the induction or upregulation of MICs may promote 
tumor surveillance by engaging the activating receptor NKG2D 
on CD56+ NKT-like cells in leukemia patients and solid tumors. 
Also, there is evidence that the most important membrane-bounded 
NKG2DL ( MICA) was prevalent only in low-grade cancers and 
may be released into the tumor stroma and circulation in high-
grade cancers as sMICA (soluble MICA) (46). 
In conclusion, based on the fact that the frequency of 
NKG2D+CD56+ NKT cells and MFI of NKG2D expression on 
these cells were signifi cantly lower in patients with metastatic 
colorectal cancer compared to healthy controls, it appears that 
sMICs may impact all NKG2D+ lymphocytes such as CD3+CD56+ 
NKT cells in the same manner, certainly in the advanced stages of 
cancer. These fi ndings strengthen the hypothesis that NKT cells 
can play a substantial role in protection against human colorectal 
cancer and this opens up avenues of approach for novel studies 
about elucidating the other aspects of tumor surveillance in CRC 
progression and immunotherapy. 
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